Department of Surgery, School of Medicine, Cheeloo College of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan, 250012, Shandong, China.
Department of Organ Transplantation, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Wenhuaxi Road, Jinan, 250012, Shandong, China.
Surg Endosc. 2022 Jun;36(6):3721-3731. doi: 10.1007/s00464-021-08686-6. Epub 2021 Aug 16.
Laparoscopic surgery (LS) for hilar cholangiocarcinoma (HCCa) remains under development, and its feasibility and safety remain controversial. This study therefore evaluated the outcomes of this technique and compared them to those of open surgery (OS).
In total, 149 patients underwent surgical resection for HCCa at our center between February 2017 and September 2020. After screening and propensity score matching, 47 OS group patients and 20 LS group patients remained, and their baseline characteristics, pathologic findings, surgical outcomes, and long-term outcomes were compared.
The baseline characteristics and pathologic findings were comparable between the two groups. The mean incision length was longer in the OS group than in the LS group (21.0 cm vs. 13.2 cm, P < 0.001). No significant differences were observed in the other surgical outcomes between the two groups. Regarding long-term outcomes, the overall survival rate and disease-free survival rate of the OS group were significantly higher than those of the LS group (P = 0.0057, P = 0.043). However, the two groups had significantly different follow-up times (19.2 months vs. 14.7 months, P = 0.041).
LS for HCCa is technically achievable, and our study revealed that it is equivalent to OS in terms of short-term outcomes but was poorer in terms of long-term outcomes.
腹腔镜手术(LS)治疗肝门部胆管癌(HCCa)仍在发展中,其可行性和安全性仍存在争议。本研究因此评估了该技术的结果,并将其与开放手术(OS)的结果进行了比较。
在我们中心,共有 149 例 HCCa 患者于 2017 年 2 月至 2020 年 9 月接受了手术切除。经过筛选和倾向评分匹配,保留了 47 例 OS 组患者和 20 例 LS 组患者,比较了他们的基线特征、病理发现、手术结果和长期结果。
两组的基线特征和病理发现相似。OS 组的平均切口长度长于 LS 组(21.0cm 比 13.2cm,P<0.001)。两组其他手术结果无显著差异。关于长期结果,OS 组的总生存率和无病生存率明显高于 LS 组(P=0.0057,P=0.043)。然而,两组的随访时间有显著差异(19.2 个月比 14.7 个月,P=0.041)。
LS 治疗 HCCa 在技术上是可行的,本研究表明,它在短期结果方面与 OS 相当,但在长期结果方面较差。